Senior Accountant

Senior Manager, Formulation Scientist

Director, Field Health Economics & Outcomes Research (HEOR) Scientist

Director, Total Rewards

Senior Manager, Pharmacovigilance Quality Assurance (PV QA)

Associate Medical Director, Drug Safety and Pharmacovigilance (PV)

Senior Medical Director, Clinical Development (MD Required)

Senior Medical Science Liaison (Sr. MSL) / South Central

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

ADAXION Therapeutics

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AS2 Bio Inc

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Adiso Therapeutics

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aera Therapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Akttyva Therapeutics

Alamar Biosciences

Aldebaran Therapeutics

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Nuvalent is using structure-based drug discovery to create precision medicines for cancer patients. Kinase inhibitors have driven the target therapy revolution in oncology, however, clinical utility is limited by the kinase resistance and selectivity problems. The former is caused by cancer mutations in kinases that become resistant to inhibitors and the latter is due to the similar structural drug binding site of different kinases causing off-target effects. Nuvalent is overcoming the challenges of resistance and selectivity by using structure-based design with clinical insight to find small molecules that inhibit clinically proven kinase targets. Nuvalent’s most advanced drug, NVL-520, targets the kinase ROS1 and is being investigated for patients with non-small cell lung cancer.

<p>Nuvalent is using structure-based drug discovery to create precision medicines for cancer patients. Kinase inhibitors have driven the target therapy revolution in oncology, however, clinical utility is limited by the kinase resistance and selectivity problems. The former is caused by cancer mutations in kinases that become resistant to inhibitors and the latter is due to the similar structural drug binding site of different kinases causing off-target effects. Nuvalent is overcoming the challenges of resistance and selectivity by using structure-based design with clinical insight to find small molecules that inhibit clinically proven kinase targets. Nuvalent’s most advanced drug, NVL-520, targets the kinase ROS1 and is being investigated for patients with non-small cell lung cancer.</p>


Find a biotech startup job.